Imaging Biometrics Limited (LON: IBAI), through its US-based subsidiary Imaging Biometrics LLC, a provider of quantitative imaging and novel therapeutics for CNS malignancies, on Monday announced a soft close to its Phase 1 clinical trial evaluating oral gallium maltolate (GaM) for relapsed or refractory glioblastoma in adults. Recruitment has now ceased, though the trial remains active for enrolled patients.

The soft close follows sufficient patient enrolment to meet statistical and operational targets, allowing the company to move forward with data consolidation, endpoint analysis and preparation for a Phase 2 trial. Final internal approvals from the Medical College of Wisconsin Cancer Center are pending.

Oral GaM, administered once daily at home, targets iron metabolism in tumour cells and has shown a favourable safety profile. Its differentiated mechanism and tolerability highlight its potential as a new treatment option in glioblastoma care.

Imaging Biometrics is currently assessing independent financing options for Phase 2 development while also pursuing strategic partnerships. Further updates will be provided as the trial progresses.